GUARDANT HEALTH, INC.
PALO ALTO, CA

Guardant Health, Inc. is a pioneering biotechnology company specializing in genomic cancer diagnostics to support personalized cancer care. Founded on April 9, 2014, and incorporated under a Filed Number F14000001559, the company is classified as FORP (Foreign Corporation for Profit) with its mailing address at 3100 Hanover Street, Palo Alto, CA, 94304, U.S. Guardant Health provides a groundbreaking genomic test that offers oncologists precise insights into patients' cancer profiles. This test assists in identifying suitable approved targeted therapies and potential clinical trial options without the inherent costs and risks associated with traditional tissue biopsies. The results are delivered through an enhanced Provider Portal, featuring tools like the Tumor Response Map to provide actionable, meaningful data for patient care. Headquartered in Palo Alto but originally based in Delaware (home state), Guardant Health is overseen by key officers including Helmy Eltoukhy and Amirali Talasaz as Co-CEOs, along with CFO Michael Bell. The company achieved a significant milestone with its reinstatement on October 20, 2015. For further information or inquiries, Guardant Health can be contacted via phone at (855) 698-8887 or (888) 974-4258. Additional details about their offerings and corporate developments are accessible through their official website: guardanthealth.com.